Sun Pharmaceutical Industries Ltd. has reported financials for the second quarter and first half ending September 30, 2017.

Highlights of 2QFY18 consolidated financials.

  • Sales/income from operations at Rs. 6590 crore, de-growth of 15 percent over the same quarter last year
  • India sales at Rs. 2221 crore, growth of 11 percent over 2Q last year
  • US finished dosage sales at Rs. 2070 crore, down by 44 percent over 2Q last year
  • Emerging markets sales at Rs. 1313 crore, up by 16 percent over 2Q last year
  • Rest of world sales at Rs. 743 crore, growth of 40 percent over 2Q last year
  • R&D investments at Rs. 511 crore (7.7 percent of sales) compared to Rs. 570 crore (7.4 percent of sales) for 2QFY17
  • EBITDA at Rs. 1315 crore, resulting EBITDA margin of 20 percent
  • Net profit for the quarter at Rs. 912 crore, down 59 percent over 2Q last year, resulting net profit margin of 14 percent

Highlights of 1HFY18 consolidated financials.

  • Sales/income from operations at Rs. 12,757 crore, de-growth of 19 percent over the same period last year
  • India sales at Rs. 3982 crore, up by 3 percent over 1H last year
  • US finished dosage sales at Rs. 4422 crore, down by 43 percent over 1H last year
  • Emerging markets sales at Rs. 2432 crore, up by 13 percent over 1H last year
  • Rest of World sales at Rs. 1514 crore, growth of 39 percent over 1H last year
  • EBITDA at Rs. 2369 crore, resulting EBITDA margin of 18.6 percent

Net profit for the 1HFY18 at Rs. 487 crore, was adversely impacted by settlements with certain plaintiffs related to the Modafinil antitrust litigation in the United States, with the settlement amounting to Rs. 951 crore reported in 1QFY18. Excluding the Modafinil settlement, the adjusted net profit for 1HFY18 was at Rs. 1438 crore, down 66 percent over 1H last year, with resulting adjusted net profit margin of 11.3 percent


10 Diagnostic Imaging Trends for 2018

Best of 2017 Medical

 

Digital version